Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumor cell vaccine and preparation method thereof

A tumor cell vaccine and tumor cell technology, applied in the field of biological therapy, can solve problems such as huge operation costs, and achieve the effects of low cost, simple preparation, and short preparation cycle

Inactive Publication Date: 2018-06-19
上海赛群生物科技有限公司
View PDF11 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Such a strategy represents the direction of cancer treatment, however, the cost of its operation is huge, both in terms of time and money

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The preparation of embodiment 1 tumor vaccine

[0029] 1.1 Experimental materials

[0030] sp2 / 0 cells, derived from ATCC in the United States; mannan peptide - purchased from Shanghai Yuanye Biotechnology Co., Ltd. 0.1mol / L, pH5.0), purchased from Shanghai Yuanye Biotechnology Co., Ltd.

[0031] 1.2 Experimental steps

[0032] In this example, mannan peptides were used to directly modify sp2 / 0 cells, and the specific operations were as follows:

[0033] will be 10 7 Add 1 sp2 / 0 cell, 1 mg of mannan peptide, and 1 mg of EDC to 1 ml of MES buffer (0.1 mol / L, pH 5.0), and mix well on a shaker at room temperature. After reacting for 2 hours, the modified sp2 / 0 cells are obtained, and then the cells are inactivated, and prepared into any pharmaceutically acceptable vaccine injection by conventional vaccine preparation methods to obtain a tumor vaccine.

Embodiment 2

[0034] The preparation of embodiment 2 tumor vaccines

[0035] 1.1 Experimental materials

[0036] sp2 / 0 cells, derived from ATCC in the United States; mannan peptide-purchased from Shanghai Yuanye Biotechnology Co., Ltd. 0.1mol / L), was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; streptavidin (SA), was purchased from Beijing Solaibao Technology Co., Ltd.; biotinylation reagent was purchased from Pierce Corporation, USA.

[0037] 1.2 Experimental steps

[0038] In this example, mannan peptides were used to indirectly modify sp2 / 0 cells, and the specific operations were as follows:

[0039] (1) Biotinylated sp2 / 0 cells

[0040] will be 10 7 Sp2 / 0 cells and 10-200 micrograms of biotinylation reagent were added to 1 ml of PBS (pH 7.6), and mixed continuously at room temperature. After 2 hours of reaction, the cells were collected by centrifugation at 800-1500 rpm for 5 minutes. Then, wash repeatedly twice with PBS to remove the residual biotinylation reagent in the ...

Embodiment 3

[0045] Example 3 Tumor Vaccines Used in Immunization Experiments

[0046] 1.1 Experimental animals

[0047] BALB / C mice were purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences. Sp2 / 0 tumor cells are derived from BALB / C mice, so they have homology. Inoculation into BALB / C mice resulted in tumorigenesis.

[0048] 1.2 Immune response

[0049] Ten mice were divided into two groups, the experimental group and the control group, with 5 mice in each group. The experimental group received sp2 / 0 cell vaccine (~10 6 cells), and the control group received PBS. Two immunizations were performed with an interval of 6 days (D1, D7). Subcutaneous injection on the inner thigh, two points, 0.25 ml each.

[0050] 1.3 Tumor cell inoculation

[0051] On day 12, all mice were inoculated with unmodified sp2 / 0 cells (10 5 cells / per mouse), abdominal inoculation. Then observe the tumor development.

[0052] 1.4 Experimental results

[0053] The control group al...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biotherapy, and especially relates to a tumor cell vaccine and a preparation method thereof. According to the invention, molecule in-vitro modified tumor cells can indentified by using antigen presenting cells, the modified tumor cell vaccine can be identified by the antigen presenting cell in vivo, and then is subjected to phagocytosis; an endocytosed tumor cell content (comprising tumour-related antigen molecule and neoantigenic peptide) is processed by the antigen presenting cell, and then is presented or shown on the surface of the cell, then the corresponding immunization effect cell can be activated, an integral reaction of an immunization system starts, and purposes of restricting tumour development and treating tumour can be reached. The methodhas the advantages of simple preparation, low cost, and short preparation period, and provides the novel and effective tumor vaccine.

Description

technical field [0001] The invention relates to the field of biological therapy, in particular to a tumor cell vaccine and a preparation method thereof. Background technique [0002] The technology of immune cells to treat cancer can be divided into passive immunization and active immunization. Passive immunization uses immune effector cells activated in vitro, mainly CD8-T cells and their derivatives, which directly attack tumor cells after infusion into the body. The main technologies in this area are CAR-T (chimeric antigen receptor-T cells), CTL (cytotoxic T lymphocytes), TCR-T (T cell receptor (TCR) chimeric T cells), TIL (tumor infiltrating lymphocytes) and other techniques. Clinical performance of these cells has been mixed. Except that CAR-T is effective against some blood cancers, the FDA has approved two CAR-T products for marketing, and the others are still in the research or clinical trial stage. A fact that cannot be ignored is that none of these cells are i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/385A61P35/00
CPCA61K39/0011A61K39/385A61K2039/5152A61K2039/6031A61K2039/6056
Inventor 张世明邱列群
Owner 上海赛群生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com